CalciMedica reports Q3 EPS (52c), consensus (41c)

Cash, cash equivalents, and short-term investments were $14.1M as of September 30. The Company expects its cash position to be sufficient to fund its current operating plan into the second half of 2026. “Enrollment continues in our Phase 2 KOURAGE trial evaluating Auxora in patients with AKI with respiratory failure, and we look forward to sharing data in the first half of 2026. As we approach this milestone, we are encouraged by AKI animal model data recently shared at ASN and results in PAH animal models published in JCI Insight, both of which provide further mechanistic rationale for CRAC channel inhibition as a promising approach for treating AKI,” said Rachel Leheny, CEO of CalciMedica (CALC). “Additionally, discussions with the FDA have been positive regarding our program in AP. We expect our recently announced collaboration with Telperian and its AI-driven analytics platform will enable us to leverage insights from completed Auxora trials to optimize the design of our pivotal trial in AP, which we expect to finalize in the first half of 2026.”